Methods of reducing mammographic breast density and/or breast cancer risk
First Claim
1. A method of reducing breast pain in a patient in need thereof, comprising administering to the patient:
- i) an effective amount of androgenic agent selected from the group consisting of testosterone, methyltestosterone, testosterone undecanoate, testosterone propionate, testosterone cypionate, and testosterone enanthate; and
ii) an effective amount of an aromatase inhibitor selected from the group consisting of;
exemestane, formestane, anastrozole, letrozole, vorozole, and fadrozole;
wherein the method mitigates the treated patient'"'"'s risk of developing breast cancer.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-memopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
31 Citations
28 Claims
-
1. A method of reducing breast pain in a patient in need thereof, comprising administering to the patient:
-
i) an effective amount of androgenic agent selected from the group consisting of testosterone, methyltestosterone, testosterone undecanoate, testosterone propionate, testosterone cypionate, and testosterone enanthate; and ii) an effective amount of an aromatase inhibitor selected from the group consisting of;
exemestane, formestane, anastrozole, letrozole, vorozole, and fadrozole;wherein the method mitigates the treated patient'"'"'s risk of developing breast cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
Specification